TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02645188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cueing
Description: Verbal and tactile cueing to enhance gluteus maximus recruitment
Study: NCT04025580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax
Description: Seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluvirin
Description: Seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose
Description: Seasonal influenza vaccine for adults ages 65 and older
Study: NCT06352164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: The investigators selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
Study: NCT03377309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fycompa
Description: Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
Study: NCT01801735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Test Capsules
Study: NCT02344004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAI (Liposomal Amikacin for Inhalation) 590 mg
Description: LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
Study: NCT02995954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril/Amlodipine
Description: Single table containing Perindopril/Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril/Amlodipine
Description: Single table containing Perindopril/Amlodipine
Study: NCT01768117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
Study: NCT04618328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid
Description: ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
Study: NCT02165254

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PLUS
Description: 1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LITE
Description: 1 hour tai chi session 3 times a week (weeks 1-12)
Study: NCT04463017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU6
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HU6
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Study: NCT05638997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument assisted manipulation + Core exercises
Description: The effect of Instrument assisted manipulation on chronic non-spesific low back pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with movement + Core exercises
Description: The effect of Mulligan mobilization with movement on chronic non-spesific low back pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core exercises
Description: The effect of core exercises on chronic non-spesific low back pain
Study: NCT02939170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A Multifocal Contact Lenses with Molded Mark

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A Multifocal Contact Lenses
Study: NCT00722930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y90 Ibritumomab Tiuxetan
Description: Consolidation with Y90 Ibritumomab Tiuxetan
Study: NCT01798121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: To compare new PPD to reference standard material
Description: Aplisol@ will be compared to reference standard material

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: To compare new PPD to reference standard material
Description: Aplisol@ will be compared to reference standard material

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reference standard
Description: Response of reference standard material compared to Aplisol@.
Study: NCT04509115

Intervention type: DRUG
Intervention: Short-acting opioid prescription for acute pain
Description: Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
Study: NCT02084056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC
Description: Linagliptin/Metformin FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC
Description: Linagliptin/Metformin FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC
Description: Linagliptin/Metformin FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC
Description: Linagliptin/Metformin FDC
Study: NCT01952054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120 mg subcutaneously on Day 1 of every 28 day cycle.
Study: NCT03522480

Intervention type: DEVICE
Group type: OTHER
Intervention: Jamboxx Respiratory Therapy Device
Description: The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jamboxx Respiratory Therapy Device
Description: The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.

Intervention type: OTHER
Group type: OTHER
Intervention: Autogenic Draining Training
Description: A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
Study: NCT03174912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical BCG instillation
Description: ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical BCG instillation
Description: ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
Study: NCT02742636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
Study: NCT03333239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychodynamic psychotherapy
Description: the intervention follows the published in german manual: Psychoanalytische Behandlung von Kindern und Jugendlichen mit Angststörungen und Depressionen: Behandlungsmanual (Baumeister-Duru, Hofmann, Timmermann \& Wulf, 2013)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral psychotherapy
Description: the interventions follow the published in german manuals: Depression (Ihle, Groen, Walter, Esser, \& Petermann, 2012) and Soziale Ängste und Leistungsängste (Büch, Döpfner, \& Petermann, 2015)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychodynamic family intervention
Description: the intervention follows an adapted version of the manual: Chimp´s - Children of mentally ill parents (Wiegand-Gefe, Halverscheid, \& Plass, 2011)
Study: NCT02279069

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4-roll canne

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-roll canne
Study: NCT02601664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Intervention
Description: pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCI
Description: Conventional PCI
Study: NCT02070588

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
Study: NCT01197859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Definitive Contact Lens
Description: Daily wear contact lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Biofinity
Description: Daily wear contact lens
Study: NCT02550717

Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Low-dose ASA for secondary prevention of cardiovascular events

Intervention type: DRUG
Intervention: Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
Description: Secondary prevention of cardiovascular events
Study: NCT04246684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, 130 mg/m2
Description: day1every three weeks (optional)
Study: NCT02876432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: 100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham electroacupuncture
Description: The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
Study: NCT01599637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGE025
Description: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
Study: NCT01602562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VACV tablets (Adults or pediatrics) or granules (pediatrics)
Description: A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
Study: NCT02825862

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Question-behaviour effect (for affective attitudes)
Description: Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Question-behaviour effect (negatively-worded attitudes)
Description: Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
Study: NCT02849717

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise for Cancer Patients
Description: a standardized, daily, home-based, progressive exercise program
Study: NCT01690598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
Study: NCT02731053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blues program
Description: Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
Study: NCT02558504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oesophagectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Study: NCT00700973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Violence Prevention Intervention
Description: This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Substance use disorder usual care
Study: NCT00837798

Intervention type: DEVICE
Intervention: CRM Device
Description: Pacemaker, ICD, or CRT device
Study: NCT01959334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon (NG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon IM
Study: NCT01424904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DGB-01 Supplementation
Description: Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.
Study: NCT03109145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menopause educational secure messaging
Description: Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
Study: NCT03520946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg iv over 60 min on d1+15, q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: 35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS 102
Description: 35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
Study: NCT03887390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Medication Choice
Description: The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.
Study: NCT00411684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDB-2914
Study: NCT01040910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: smoking of cannabis
Description: smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: smoking cigarettes with placebo
Description: smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
Study: NCT03933202

Intervention type: DRUG
Intervention: Cladribine Tablets
Description: No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Study: NCT02261935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Existing home care nursing practice
Description: Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice support tool intervention
Description: The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.~Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs.